…what proportion of your MS patients could be diagnosed with SPMS? < 10% 11-20% 21-35% 36-50% >50% 2. In your experience, what proportion of patients have active disease at the time of SPMS diagnosis? < 20% 20-40% 41-50% 50-60% >60% 3. How do you identify active disease in your SPMS patients? Relapses New MRI lesions Increased MRI lesion load Brain atrophy >20% worsening in T25FW or 9HPT >4-point worsening on SDMT 4. Do you believe that SPMS patie…

…generally younger (63.2% aged < 50 years), with RRMS (75.1%) and with mild-to-moderate disability (77.1% with EDSS 0-6). One-third of patients were receiving anti-CD20 therapies; 11.5% were untreated. To date, there have been 48 deaths (3.12%). Risk factors for COVID-19 hospitalization were older age (PR 1.55 if aged 50-70, 1.70 if aged >70), progressive disease (PR 1.70), and EDSS >6 (PR 1.68). Risk factors for ICU admission were older age (PR 1…

…ociated with MS risk. Novel DMTs in development Ponesimod: This sphingosine-1-phosphate (S1P) receptor-1 modulator is in development for relapsing MS. Results from the phase III OPTIMUM trial of ponesimod versus teriflunomide were announced at last year’s ECTRIMS but the data have not yet been published. In an update of MRI findings, ponesimod was associated with significant reductions in the number of new/enlarging T2 lesions (rate ratio 0.44), n…

…f patients on continuous DMF 240 mg BID for up to 13 years remained relapse-free with minimal disability, according to the results of the ENDORSE extension study (Gold et al. ECTRIMS 2020; abstract FC02.05). ARR was 0.14. A total of 60% of patients were relapse-free with continuous DMF; an additional 20% experienced one relapse. Moreover, 72% experienced no 24-week confirmed disability progression over 10 years. The proportion of patients with an…